| Schedule of accrued and other liabilities |
Accrued and other liabilities consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
|
2024 |
|
2023 |
Accrued incentive compensation |
|
$ |
1,171 |
|
$ |
1,203 |
Other accrued liabilities |
|
|
445 |
|
|
625 |
Accrued legal and accounting fees |
|
|
637 |
|
|
791 |
Accrued payroll and benefits |
|
|
198 |
|
|
149 |
Total |
|
$ |
2,451 |
|
$ |
2,768 |
|
| Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net loss per share attributable to common stockholders |
The following table includes the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Numerator |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(17,243) |
|
$ |
(5,509) |
|
$ |
(9,853) |
|
$ |
(20,722) |
Less: Series A accumulated dividends |
|
|
(530) |
|
|
(530) |
|
|
(1,591) |
|
|
(1,591) |
Less: Series B accumulated dividends |
|
|
(838) |
|
|
(838) |
|
|
(2,513) |
|
|
(2,513) |
Net loss attributable to common stockholders, basic |
|
$ |
(18,611) |
|
$ |
(6,877) |
|
$ |
(13,957) |
|
$ |
(24,826) |
Net loss attributable to common stockholders, diluted |
|
$ |
(18,611) |
|
$ |
(6,877) |
|
$ |
(13,957) |
|
$ |
(24,826) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
|
|
11,712 |
|
|
11,473 |
|
|
11,645 |
|
|
11,466 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
|
|
11,712 |
|
|
11,473 |
|
|
11,645 |
|
|
11,466 |
Net loss per share attributable to common stockholders, basic |
|
$ |
(1.59) |
|
$ |
(0.60) |
|
$ |
(1.20) |
|
$ |
(2.17) |
Net loss per share attributable to common stockholders, diluted |
|
$ |
(1.59) |
|
$ |
(0.60) |
|
$ |
(1.20) |
|
$ |
(2.17) |
|
| Schedule of outstanding securities considered anti-dilutive |
The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Convertible preferred stock |
|
5,003 |
|
5,003 |
|
5,003 |
|
5,003 |
Common stock options |
|
1,473 |
|
1,804 |
|
1,775 |
|
1,781 |
Warrants for common stock |
|
131 |
|
6 |
|
131 |
|
6 |
Total |
|
6,607 |
|
6,813 |
|
6,909 |
|
6,790 |
|